either idarubicin or daunorubicin (n=11) was 81.8%; the CR rate was 54.5%. Median overall survival
has not been reached.
Conclusions: Gilteritinib can be safely combined with chemotherapy and given as maintenance
therapy in patients with ND AML. High response rates were observed in FLT3mut+ patients regardless
of anthracycline type or gilteritinib administration schedule.
